Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | BCR | P11274 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24053406 | 0.83 | MAPK10 (0.38) | SMN1; SMN2RPS6KA5MAPK10PDE10AABL1 | |
| SCHEMBL30166321 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTRPS6KA5ALDH1A1L3MBTL1 | |
| SCHEMBL24054006 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTRPS6KA5ALDH1A1L3MBTL1 | |
| SCHEMBL24054370 | 0.75 | KMT2A (0.56) | SMN1; SMN2MAPTALDH1A1L3MBTL1KMT2A | |
| SCHEMBL25694936 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTRPS6KA5ALDH1A1L3MBTL1 | |
| SCHEMBL30166311 | 0.75 | KMT2A (0.56) | SMN1; SMN2MAPTALDH1A1L3MBTL1KMT2A | |
| SCHEMBL31205839 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTRPS6KA5ALDH1A1L3MBTL1 | |
| SCHEMBL25695340 | 0.74 | KDM4E (0.47) | SMN1; SMN2MAPTPDE10AALDH1A1KMT2A | |
| SCHEMBL25695707 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTRPS6KA5ALDH1A1L3MBTL1 | |
| SCHEMBL24054252 | 0.73 | SYK (0.36) | MAPK10PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454529-B2 | Piperazine cyclic ureas | Sironax Ltd. (KY) | 2025-10-28 | — | — | US | disclosed |
| CN-115697991-B | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-07-04 | — | — | US | disclosed |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-07-04 | — | — | US | disclosed |
| CN-117500795-A | Receptor interacting protein 1 inhibitor, preparation and application thereof | 维泰瑞隆有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4308555-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-01-24 | — | — | EP | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-115697991-A | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022194259-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2022-09-22 | — | — | WO | disclosed |
| WO-2021233397-A1 | PIPERAZINE CYCLIC UREAS | Sironax Ltd. (KY) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454529-B2 | Piperazine cyclic ureas | RIPK1, RIPK3, RIPK4 | SMN1; SMN2 2977/4885MAPT 2881/4885RPS6KA5 333/4885 |
| US-20230203019-A1 | Piperazine Cyclic Ureas | RIPK1, RIPK3, RIPK4 | SMN1; SMN2 2977/4885MAPT 2881/4885RPS6KA5 333/4885 |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK4 | SMN1; SMN2 2735/4885MAPT 2925/4885RPS6KA5 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.